Harpoon Therapeutics (HARP) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares.
View HARP analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month price targets for Harpoon Therapeutics' shares. Their HARP share price forecasts range from $1.50 to $8.00. On average, they expect the company's stock price to reach $4.71 in the next year. This suggests a possible upside of 512.2% from the stock's current price.
View analysts price targets for HARP or view top-rated stocks among Wall Street analysts.

Harpoon Therapeutics' stock was trading at $0.7257 on January 1st, 2023. Since then, HARP shares have increased by 6.1% and is now trading at $0.77.
View the best growth stocks for 2023 here.

Harpoon Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 417,700 shares, a decline of 45.1% from the April 30th total of 761,200 shares. Based on an average daily volume of 226,400 shares, the short-interest ratio is currently 1.8 days. Approximately 1.7% of the shares of the stock are short sold.
View Harpoon Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our HARP earnings forecast.

Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Thursday, May, 11th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.11. The company had revenue of $8.58 million for the quarter, compared to analysts' expectations of $8.81 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 473.13% and a negative net margin of 169.83%.

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Harpoon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.14%), Renaissance Technologies LLC (0.52%), Acadian Asset Management LLC (0.30%), Sequoia Financial Advisors LLC (0.27%), Bailard Inc. (0.17%) and Two Sigma Investments LP (0.15%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology and Ronald Hunt.
View institutional ownership trends.

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HARP stock can currently be purchased for approximately $0.77.

Harpoon Therapeutics (NASDAQ:HARP) has a market capitalization of $24.72 million and generates $31.92 million in revenue each year. The company earns $-67,730,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.harpoontx.com. The company can be reached via phone at (650) 443-7400 or via email at ir@harpoontx.com.